Emodin inhibits epithelial to mesenchymal transition in epithelial ovarian cancer cells by regulation of GSK-3β/β-catenin/ZEB1 signaling pathway

Oncology Reports
Chen HuPeishu Liu

Abstract

Emodin (EMO) has been shown to possess pleiotropic anticancer capabilities in many types of cancer, including epithelial ovarian cancer (EOC). Inhibitory efficacy of EMO on EOC invasion and migration was previously observed, however, the underlying mechanisms have not been completely elucidated. The present study is aimed to explore the mechanisms. Transwell assay demonstrated that EMO significantly inhibited A2780 and SK-OV-3 cell invasion. Western blot analysis was performed to detect the expression levels of epithelial to mesenchymal transition (EMT)-related markers. We found that EMO treatment dose-dependently upregulated E-cadherin, keratin and downregulated N-cadherin, vimentin, matrix metalloproteinase-9 (MMP-9) and matrix metalloproteinase-2 (MMP-2) to repress EMT. Mechanistically, EMO could inhibit glycogen synthase kinase 3β (GSK-3β) phosphorylation, decrease total β-catenin protein levels and subsequently downregulate transcription factor zinc finger E-box binding homeobox 1 (ZEB1) expression. These effects of EMO were weakened when the cells were pretreated with SB216763, an inhibitor of GSK-3β kinase. Besides, we utilized small interfering RNA (siRNA) to downregulate ZEB1 expression. We found that treatment of ZEB1...Continue Reading

References

Feb 24, 2006·Nature Reviews. Molecular Cell Biology·Jean Paul Thiery, Jonathan P Sleeman
Oct 5, 2006·Medicinal Research Reviews·Gopal SrinivasPriya Srinivas
May 18, 2007·Nature Reviews. Cancer·Héctor PeinadoAmparo Cano
Jun 13, 2008·Advances in Experimental Medicine and Biology·Jurgen M J PiekRené H M Verheijen
Nov 26, 2008·Oncogene·G Moreno-BuenoA Cano
Jan 21, 2009·Cancer Metastasis Reviews·Otto SchmalhoferThomas Brabletz
Nov 3, 2009·Cancer Letters·Daniele VergaraMichel Salzet
Mar 10, 2010·Clinical & Experimental Metastasis·Sivan ElloulReuven Reich
Jun 26, 2010·Circulation Research·Tata Purushothama Rao, Michael Kühl
Nov 15, 2011·Proceedings of the National Academy of Sciences of the United States of America·Ester Sánchez-TillóAntonio Postigo
Dec 22, 2012·Nature Reviews. Cancer·Jamie N Anastas, Randall T Moon
Jan 12, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Susana Banerjee, Stanley B Kaye
Jan 25, 2013·Nature Reviews. Cancer·Bram De Craene, Geert Berx
Jul 23, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Md Asaduzzaman KhanJunjiang Fu
Oct 16, 2013·Gynecologic Oncology·Rebecca C ArendDonald J Buchsbaum
Oct 26, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Tzong-Der WayChi-Tang Ho
Nov 22, 2013·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Dengyu ChenJun Dou
Apr 26, 2014·The Journal of Clinical Investigation·Rachel A DavidowitzJoan S Brugge
Sep 11, 2014·European Journal of Pharmacology·Thacker Pooja, Devarajan Karunagaran
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Mar 19, 2015·PloS One·Pooja Chandrakant Thacker, Devarajan Karunagaran
May 31, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nastaran Mohammadi Ghahhari, Sadegh Babashah

❮ Previous
Next ❯

Citations

Feb 14, 2019·Technology in Cancer Research & Treatment·Raúl García-VázquezCésar López-Camarillo
Nov 27, 2019·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Ting WangGuo-Qiang Wen
May 15, 2018·Nanomaterials·Tamara KrajnovićGoran N Kaluđerović
May 8, 2020·Oxidative Medicine and Cellular Longevity·Xiaoji CuiYing Liang
Nov 11, 2020·Biochemical and Biophysical Research Communications·Lu XuYaping Tian
Jun 3, 2021·Cancers·Esra Küpeli AkkolRaffaele Capasso
Jul 27, 2021·Phytochemistry·Ruchi Badoni SemwalAlvaro Viljoen
Dec 12, 2020·Acta Pharmaceutica Sinica. B·Rujing ChenKaili Hu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.

Adherens Junctions

An adherens junction is defined as a cell junction whose cytoplasmic face is linked to the actin cytoskeleton. They can appear as bands encircling the cell (zonula adherens) or as spots of attachment to the extracellular matrix (adhesion plaques). Adherens junctions uniquely disassemble in uterine epithelial cells to allow the blastocyst to penetrate between epithelial cells. Discover the latest research on adherens junctions here.